Grace Therapeutics (GRCE) Change in Cash (2019 - 2026)
Grace Therapeutics (GRCE) posted Change in Cash of -$1.7 million for Q1 2026, down 193.65% sequentially from $1.8 million in Q4 2025, and down 115.3% YoY from $11.1 million in Q1 2025.
Grace Therapeutics (GRCE) Change in Cash (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Change in Cash for 8 years, with the latest figure at -$1.7 million in Q1 2026.
- Quarterly Change in Cash fell 115.3% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.2 million (down 491.28% YoY) and the FY2026 annual result came in at -$5.2 million, down 491.28% from the prior year.
- Change in Cash retreated to -$1.7 million in Q1 2026 per GRCE's latest filing, from $1.8 million in the prior quarter.
- Over five years, Change in Cash peaked at $11.1 million in Q1 2025 and troughed at -$8.7 million in Q4 2022.
- A 5-year average of -$943294.1 and a median of -$2.7 million in 2022 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2023 and 2024: Change in Cash jumped 255.26% in 2023, then slumped 179.12% in 2024.
- Over 5 years, Change in Cash stood at -$8.7 million in 2022, then rose by 2.75% to -$8.4 million in 2023, then jumped by 51.46% to -$4.1 million in 2024, then soared by 144.15% to $1.8 million in 2025, then tumbled by 193.65% to -$1.7 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered -$1.7 million, $1.8 million, and -$3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | -3.14 Mn |
| Jun 30, 2025 | -2.13 Mn |
| Mar 31, 2025 | 11.08 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Jun 30, 2024 | -3.61 Mn |
| Mar 31, 2024 | 4.46 Mn |
| Dec 31, 2023 | -8.45 Mn |
| Sep 30, 2023 | 5.36 Mn |
| Jun 30, 2023 | -6.24 Mn |
| Mar 31, 2023 | 1.63 Mn |
| Dec 31, 2022 | -8.69 Mn |
| Sep 30, 2022 | -3.45 Mn |
| Jun 30, 2022 | 8.04 Mn |
| Mar 31, 2022 | -2.67 Mn |
| Dec 31, 2021 | -3.92 Mn |
| Sep 30, 2021 | -4.05 Mn |